{"title":"Brève : L’OMS formelle : « La meilleure arme contre la RAM est la vaccination. »","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00392-7","DOIUrl":"10.1016/S1773-035X(24)00392-7","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Page 23"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ces GLP1-like qui agissent aussi sur le cerveau","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00378-2","DOIUrl":"10.1016/S1773-035X(24)00378-2","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Page 13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Covid-19 et maladies mentales chez les personnes vaccinées et non vaccinées","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00377-0","DOIUrl":"10.1016/S1773-035X(24)00377-0","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Page 13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prise en charge de la sclérose latérale amyotrophique","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00386-1","DOIUrl":"10.1016/S1773-035X(24)00386-1","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Pages 18-19"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Brève : Loi de programmation Grand Âge : c’est pas encore ça !","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00389-7","DOIUrl":"10.1016/S1773-035X(24)00389-7","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Page 20"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biopsie liquide et/ou biopsie tissulaire en oncologie thoracique : algorithmes et perspectives","authors":"Paul Hofman","doi":"10.1016/S1773-035X(24)00397-6","DOIUrl":"10.1016/S1773-035X(24)00397-6","url":null,"abstract":"<div><h3>Résumé</h3><div>Les thérapies ciblées et les immunothérapies en oncologie thoracique, plus spécifiquement celles administrées dans le cadre des cancers pulmonaires non à petites cellules non épidermoïdes (CPNPC-NE), nécessitent la mise en évidence d’un nombre croissant de biomarqueurs prédictifs. Les molécules thérapeutiques sont, soit associées à une autorisation de mise sur le marché pour une utilisation en pratique quotidienne, soit utilisées dans le cadre d’essais cliniques. Les cibles moléculaires sont ainsi de plus en plus nombreuses à identifier, imposant d’utiliser des approches de séquençage de nouvelle génération (NGS). Ces techniques sont possibles à partir d’échantillons tissulaires et cellulaires, mais également à partir d’échantillons liquides, en particulier du sang. Les tests sanguins en oncologie ou “biopsie liquide” (BL) se font à partir de l’ADN plasmatique libre circulant et sont complémentaires des tests moléculaires tissulaires. Leur prescription répond à des recommandations internationales, mais d’autres algorithmes peuvent également se discuter. Bien que nécessaire pour une meilleure prise en charge des patients, en particulier en phase avancée ou métastatique, les BL sont encore assez peu intégrées en pratique quotidienne en Europe et en particulier en France. Cette revue aborde différents algorithmes permettant d’identifier les signatures moléculaires des CPNPC-NE à partir des biopsies tissulaires et liquides et introduit certaines limites et perspectives concernant les BL.</div></div><div><h3>Abstract</h3><div>The targeted therapies and immunotherapies in thoracic oncology, notably for non-squamous non-small cell lung cancers (NS-NSCLC), need an increase number of predictive biomarkers assessment. These treatments are associated with a marketing authorization for a daily practice use, or are administered during clinical trials. Since the molecular targets to be identified are more and more numerous, it is now necessary to use new molecular technologies corresponding to the next generation sequencing (NGS) approaches. These technologies can be developed from tissue and cellular samples, but also from biofluids, mainly from blood samples. The blood tests in oncology, so called the “liquid biopsies” are performed from plasmatic circulating free DNA and are certainly a complementary approach of the molecular testings realized from the tissue biopsies. Liquid biopsy use in lung cancer is associated with some international guidelines, but additional algorithms can be also set up. Even if necessary for a better patient taking care, notably in advanced and metastatic NSCLC patients, LB are not so much integrated in daily practice until now in Europe, notably in France. The purpose of this review is to describe the different opportunities and algorithms leading to the identification of molecular signatures in NS-NSCLC both from tissue and liquid biopsies, and, to introduce the principles limitations but also some perspe","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 567","pages":"Pages 52-60"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143182537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Choc toxique staphylococcique menstruel en France : ce que vous devez savoir","authors":"Sibyle Etievant , Anne Tristan , Gérard Lina","doi":"10.1016/S1773-035X(24)00358-7","DOIUrl":"10.1016/S1773-035X(24)00358-7","url":null,"abstract":"<div><h3>Résumé</h3><div>En France, environ trente cas de choc toxique staphylococcique menstruel sont déclarés chaque année. Cette pathologie sévère peut entraîner une hospitalisation en unité de réanimation et, plus rarement, le décès si elle n’est pas traitée rapidement. Les premiers symptômes incluent fièvre, frissons, éruption cutanée et troubles digestifs. Ce syndrome survient chez des femmes durant leurs menstruations, utilisant des protections périodiques intravaginales (tampon, coupe menstruelle, etc.) et présentant une colonisation vaginale par <em>Staphylococcus aureus</em> producteur de la toxine du choc toxique staphylococcique (TSST-1 pour <em>Toxic shock syndrome toxin-</em><em>1</em>). Cette toxine superantigénique, produite au niveau vaginal, active de façon non spécifique le système immunitaire, entraînant une libération massive de cytokines pro-inflammatoires. Le diagnostic de ce syndrome repose sur une association de critères cliniques et biologiques. Le diagnostic biologique implique l’isolement d’une souche de <em>S. aureus</em> producteur de TSST-1, généralement sur un prélèvement vaginal. Le retrait de la protection périodique intravaginale, l’administration d’une bêtalactamine antistaphylococcique et d’un antibiotique antitoxinique comme la clindamycine permettent de réduire la mortalité et les séquelles associées à cette maladie.</div></div><div><h3>Abstract</h3><div>Around 30 cases of menstrual staphylococcal toxic shock syndrome are reported each year in France. This is a severe illness that, if not rapidly treated, can result in hospitalization in intensive care and, and, less commonly, death. The initial symptoms include fever, chills, rash and digestive disorders. This syndrome occurs during menstruation, in women who use intravaginal sanitary protection (tampon, menstrual cup, etc.) and who have a vaginal carriage of <em>Staphylococcus aureus</em> producing toxic shock syndrome toxin 1 (TSST-1). This superantigenic toxin, produced in the vagina, non-specifically activates the immune system, leading to the massive release of pro-inflammatory cytokines. Diagnosis of this syndrome is based on a combination of clinical and biological criteria. Biological diagnosis typically involves the isolation of a TSST-1-producing strain of <em>S. aureus</em>, which is usually obtained from a vaginal swab. The removal of intravaginal protection, administration of an anti-staphylococcal beta-lactam antibiotic and an antitoxin such as clindamycin can reduce mortality and sequelae of the disease.</div></div>","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 566","pages":"Pages 27-33"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
